$1.03
0.96% today
Nasdaq, Nov 20, 08:43 pm CET
ISIN
US7574681034
Symbol
RDHL

RedHill Biopharma Ltd. Sponsored ADR Stock price

$1.04
-0.69 39.88% 1M
-0.86 45.26% 6M
-5.17 83.25% YTD
-5.81 84.82% 1Y
-464.26 99.78% 3Y
-8,968.96 99.99% 5Y
-12,578.96 99.99% 10Y
-11,098.96 99.99% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
-0.02 1.89%
ISIN
US7574681034
Symbol
RDHL
Industry

Key metrics

Basic
Market capitalization
$3.5m
Enterprise Value
$880.0k
Net debt
positive
Cash
$2.9m
Shares outstanding
33.3b
Valuation (TTM | estimate)
P/E
- | -
P/S
0.3 | 0.1
EV/Sales
0.1 | 0.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-26.0%
Return on Equity
176.6%
ROCE
485.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$12.1m | $38.8m
EBITDA
$-18.6m | -
EBIT
$-19.0m | $-6.6m
Net Income
$-12.4m | -
Free Cash Flow
$-8.2m
Growth (TTM | estimate)
Revenue
33.2% | 382.1%
EBITDA
-472.4% | -
EBIT
-553.9% | 54.6%
Net Income
-159.5% | -
Free Cash Flow
66.1%
Margin (TTM | estimate)
Gross
60.4%
EBITDA
-153.6% | -
EBIT
-156.7%
Net
-102.3% | -
Free Cash Flow
-67.7%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
5.8%
Employees
35
Rev per Employee
$230.0k
Show more

Is RedHill Biopharma Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

RedHill Biopharma Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a RedHill Biopharma Ltd. Sponsored ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a RedHill Biopharma Ltd. Sponsored ADR forecast:

Buy
86%
Hold
14%

Financial data from RedHill Biopharma Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
12 12
33% 33%
100%
- Direct Costs 4.80 4.80
1% 1%
40%
7.32 7.32
73% 73%
60%
- Selling and Administrative Expenses 21 21
46% 46%
177%
- Research and Development Expense 2.55 2.55
39% 39%
21%
-19 -19
472% 472%
-154%
- Depreciation and Amortization 0.37 0.37
55% 55%
3%
EBIT (Operating Income) EBIT -19 -19
554% 554%
-157%
Net Profit -12 -12
160% 160%
-102%

In millions USD.

Don't miss a Thing! We will send you all news about RedHill Biopharma Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RedHill Biopharma Ltd. Sponsored ADR Stock News

Neutral
PRNewsWire
16 days ago
RALEIGH, N.C. and TEL-AVIV, Israel , Nov. 4, 2025 /PRNewswire/ -- RedHill Biopharma Ltd.
Neutral
PRNewsWire
29 days ago
On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued listing, pursuant to Listing Rule 5550(b)(1)  Following RedHill's transaction with Cumberland Pharmaceuticals Inc., announced October 20, 2025, the Company believes that its stockholders'...
Neutral
PRNewsWire
about one month ago
Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn. , Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd.
More RedHill Biopharma Ltd. Sponsored ADR News

Company Profile

RedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Dror Ben-Asher
Employees 35
Founded 2009
Website www.redhillbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today